Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

The trial revealed that Ozempic® 1 mg significantly lowered the relative ... Ozempic®, classified as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was initially approved by the FDA ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...